A Study of HS-10382 in Patients With Chronic Myeloid Leukemia.

HS-10382 is a small molecular, oral potent, allosteric inhibitor. By binding a myristoyl site of the BCR-ABL1 protein, HS-10382 locks BCR-ABL1 into an inactive conformation. The purpose of this study is to investigate the safety/tolerability and the pharmacokinetic(PK) profile of HS-10382 in patients with chronic myeloid leukemia (CML). Anti-CML activity will also be investigated in this study.

Trial Details

NCT ID

NCT05367700

Phase

PHASE1

Sponsor

Jiangsu Hansoh Pharmaceutical Co., Ltd.

Status

RECRUITING

Cancer Type

Leukemia

Interventions

HS-10382(Part 1: Dose escalation)
HS-10382(Part 2: Dose expansion)

Locations (sample)

Wuhan, Hubei, China|30.58333,114.26667

Key Eligibility Criteria

Signed informed consent form.
Men or women aged more than or equal to (≥) 18 years, and less than (\<) 75 years.
CML-CP/AP patients with the Ph chromosome or BCR-ABL1 fusion genes.
Patient with CML-CP/AP who are resistant to or intolerant to previous TKIs therapy.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Leukemia Trials on Trialify →